QALY made clear
London – Proposed changes to NICE’s guide to its methods will make its use of cost per quality-adjusted life year (QALY) in health technology assessments clearer, the institute says. NICE officials at the institute’s annual conference in Manchester said that treatments costing less than EUR28,000 per QALY were not systematically approved. Costs higher than EUR43,000 were also not systematically rejected, the institute said. NICE describes these numbers as its threshold range for cost-effectiveness. The officials stated, however, that treatment costs exceeding this threshold will only be recommended for reimbursement in exceptional cases. Factors to be taken into account include the degree of uncertainty in incremental cost-effectiveness ratios, and whether quality of life parameters have been measured adequately.